Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about hair loss treatments, including minoxidil, finasteride, dutasteride, tretinoin, stemoxydine, adenosine, castor oil, baicalin, and bimatoprost. The user shares their nightly and morning routines and discusses the role of DHT in hair loss.

The conversation is about using topical melatonin for hair loss and seeking advice on a safe mixing solution or pre-mixed product. Specific treatments mentioned are minoxidil, finasteride, and RU58841.

The conversation is about a user dealing with androgenetic alopecia using minoxidil 5% and attempting to import Adenogen tonic from Japan, which was rejected by Spanish customs. The user seeks advice on obtaining Adenogen or Adenovital within the EU or tips for passing customs.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.

ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

The conversation discusses starting low-dose oral finasteride for hair loss, considering hormone levels and potential side effects like gynecomastia. Suggestions include using DIM for estradiol, vitamin B6 for prolactin, and lifestyle changes to optimize hormone profiles before starting treatment.

A user is seeing good results with RU58841 for hair loss, noting reduced shedding and thicker hair. They plan to use pumpkin seed oil as a solvent to avoid water content, which they believe reduces the effectiveness of anti-androgens.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

Breezula's effectiveness is uncertain, with some users skeptical about its potential and others noting its recent availability on the grey market. A user reported success with a stack of Dutasteride (oral), Minoxidil (topical), and RU58841 (topical), achieving significant hair improvement after 18 months.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

Bald men can still attract partners, as personality and confidence often outweigh hair loss. Treatments like finasteride and minoxidil are used, but self-acceptance and personal satisfaction are key.

The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.

A user from Iran reports hair growth in bald spots after using a domestic tonic containing Anageline, Trichogen, Aminexil, Caffeine, Saw Palmetto, and B vitamins, alongside Finasteride, but without Minoxidil. They prefer the tonic over Minoxidil as it doesn't make their hair greasy or cause hair fall.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

The conversation discusses alternatives to RU58841 for hair loss treatment, with suggestions including topical spironolactone, peppermint and rosemary oils, and saw palmetto. The user also considers ordering RU58841 from China but finds it too expensive.

The conversation discusses alternative and unorthodox hair loss treatments, including RU58841, nandrolone, and dianabol, as well as theoretical approaches involving high doses of estrogen and selective estrogen receptor modulators. These methods are considered extreme and potentially harmful but are explored for those unable to tolerate traditional 5-alpha reductase inhibitors.

Clascoterone 5% solution (Breezula) is a promising alternative for androgenetic alopecia, showing continued hair growth with consistent use and no significant side effects. It may be suitable for those who cannot tolerate finasteride or dutasteride, especially when trying to conceive.

Fluridil may decrease the number of androgen receptors in hair follicles by up to 95%. This suggests a different action mechanism from other non-steroidal antiandrogens like RU58841, indicating they might be used together.

Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.

Breezula® (Clascoterone) showed promising results in a Phase 2 trial for treating hair loss, being as effective as Propecia with no serious side effects. It might be released between 2021-2022, and a related acne treatment with the same active ingredient could be used in the meantime.

Finasteride can cause gynecomastia due to hormonal imbalances. Management includes consulting an endocrinologist and using aromatase inhibitors like anastrozole or supplements like DIM and zinc.

The conversation is about hair loss treatments, specifically a stack including topical Ashwagandha, Copper Peptide, Gotu Kola, Ketoconazole, and PDA. One user found Topical and Sub-Q GHK-CU effective.

The user added P5P (vitamin B6) to their shampoo to reduce scalp itch, which improved significantly. They have been using finasteride for hair loss but are exploring additional treatments like topical antiandrogens and prolactin inhibitors.

The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.

The conversation discusses the role of DHT in male hair loss and the effectiveness of treatments like Finasteride, which reduces DHT, and RU58841, which blocks DHT from binding to scalp receptors. The user debates the trade-offs between maintaining hair and having a healthy endocrine system, suggesting RU58841 might allow for both.

Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.

Hair loss treatments, including finasteride and RU58841, with humorous speculation about the cause of death for an ancient mummy that still had hair.